- Home
- CCIF vs NTHI Comparison
CCIF vs NTHI Comparison
Compare CCIF & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- NTHI
- Stock Information
- Founded
- CCIF 2011
- NTHI 2008
- Country
- CCIF United States
- NTHI United States
- Employees
- CCIF N/A
- NTHI N/A
- Industry
- CCIF Finance/Investors Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- NTHI Health Care
- Exchange
- CCIF Nasdaq
- NTHI Nasdaq
- Market Cap
- CCIF 113.2M
- NTHI 110.9M
- IPO Year
- CCIF N/A
- NTHI N/A
- Fundamental
- Price
- CCIF $6.43
- NTHI $4.75
- Analyst Decision
- CCIF
- NTHI
- Analyst Count
- CCIF 0
- NTHI 0
- Target Price
- CCIF N/A
- NTHI N/A
- AVG Volume (30 Days)
- CCIF 76.9K
- NTHI 269.9K
- Earning Date
- CCIF 01-01-0001
- NTHI 01-01-0001
- Dividend Yield
- CCIF 25.90%
- NTHI N/A
- EPS Growth
- CCIF N/A
- NTHI N/A
- EPS
- CCIF N/A
- NTHI N/A
- Revenue
- CCIF N/A
- NTHI $79,990.00
- Revenue This Year
- CCIF N/A
- NTHI N/A
- Revenue Next Year
- CCIF N/A
- NTHI N/A
- P/E Ratio
- CCIF N/A
- NTHI N/A
- Revenue Growth
- CCIF N/A
- NTHI 13.52
- 52 Week Low
- CCIF $7.43
- NTHI $3.20
- 52 Week High
- CCIF $10.16
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- CCIF 51.09
- NTHI N/A
- Support Level
- CCIF $6.38
- NTHI N/A
- Resistance Level
- CCIF $6.48
- NTHI N/A
- Average True Range (ATR)
- CCIF 0.11
- NTHI 0.00
- MACD
- CCIF 0.03
- NTHI 0.00
- Stochastic Oscillator
- CCIF 77.94
- NTHI 0.00
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").